ANIB1 overexpression
|
Breast Cancer
|
ANIB1 overexpression
|
Breast Cancer
|
tamoxifen Resistant: B - Late Trials
|
tamoxifen Resistant: B - Late Trials
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
GANT1 Sensitive: D – Preclinical
|
GANT1 Sensitive: D – Preclinical
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
GANT61 Sensitive: D – Preclinical
|
GANT61 Sensitive: D – Preclinical
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
Hedgehog cell-signalling pathway inhibitor Sensitive: D – Preclinical
|
Hedgehog cell-signalling pathway inhibitor Sensitive: D – Preclinical
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
cyclopamine Sensitive: D – Preclinical
|
cyclopamine Sensitive: D – Preclinical
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
ANIB1 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
sonidegib Sensitive: D – Preclinical
|
sonidegib Sensitive: D – Preclinical
|